Highlights
- •The blood brain barrier is a limiting factor to treating cerebral metastasis.
- •Targeted delivery by convection enhanced therapy bypasses the blood brain barrier.
- •Delivery of drugs in hyperosmotic solutions has a passive tumor targeting effect.
Abstract
Advances in therapies for breast cancer with cerebral metastases has been slow, despite
this being a common diagnosis, due to limited drug delivery by the blood brain barrier.
Improvements in drug delivery for brain metastasis to target the metastases and bypass
the blood brain barrier are necessary. In our study, we delivered an inhibitor of
chemokine receptor 4 by convection enhanced delivery in a hyperosmotic solution to
prevent brain metastasis in a mouse model of metastatic breast cancer. We found the
inhibitor limited metastatic disease and more interestingly, the hyperosmotic solution
targeted tumor tissue allowing for a higher accumulation of the therapy into tumor
tissue. This finding has the potential to improve delivery of chemotherapeutic agents
to brain metastases.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Clinical NeuroscienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- CNS metastases in breast cancer.J Clin Oncol. 2004; 22: 3608-3617https://doi.org/10.1200/JCO.2004.01.175
- Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.Breast Cancer Res Treat. 2017; 162: 169-179https://doi.org/10.1007/s10549-017-4107-x
- Breast cancer metastasis to the central nervous system.Am J Pathol. 2005; 167: 913-920https://doi.org/10.1016/S0002-9440(10)61180-7
- Brain metastasis in breast cancer: a comprehensive literature review.J Neurooncol. 2016; 1–8https://doi.org/10.1007/s11060-016-2075-3
- Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study.Clin Exp Metastasis. 2016; 34: 93-101https://doi.org/10.1007/s10585-016-9824-8
- Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies.J Neurosurg. 2017; 126: 191-200https://doi.org/10.3171/2016.1.JNS151591
- CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.Biochem Biophys Res Commun. 2007; 359: 716-722https://doi.org/10.1016/j.bbrc.2007.05.182
- An isoform of C/EBP, LIP, regulates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration.J Biol Chem. 2013; 288: 28656-28667https://doi.org/10.1074/jbc.M113.509505
- Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).J Med Chem. 2012; 55: 977-994https://doi.org/10.1021/jm200568c
- Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4.Bioorgan Med Chem. 2016; S0968–0896: 30679-30684
- Convection-enhanced delivery to the central nervous system.J Neurosurg. 2015; 122: 697-706https://doi.org/10.3171/2014.10.JNS14229
- Advances in drug delivery to high grade gliomas.Brain Pathol. 2016; 26: 689-700https://doi.org/10.1111/bpa.12423
- Neurosurgical techniques for disruption of the blood-brain barrier for glioblastoma treatment.Pharmaceutics. 2015; 7: 175-187https://doi.org/10.3390/pharmaceutics7030175
- Increased blood-brain permeability with hyperosmolar mannitol increases cerebral O2 consumption and O2 supply/consumption heterogeneity.J Cereb Blood Flow Metab. 1996; 16: 327-333https://doi.org/10.1097/00004647-199603000-00019
- Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.Neurosurg Clin N Am. 2012; 23: 323-329https://doi.org/10.1016/j.nec.2012.01.008
- Normal macromolecular clearance out of the ventricles is delayed in hydrocephalus.Brain Res. 2018; 1678: 337-355https://doi.org/10.1016/j.brainres.2017.10.013
Article info
Publication history
Published online: January 21, 2019
Accepted:
January 3,
2019
Received:
May 16,
2018
Identification
Copyright
© 2019 Elsevier Ltd. All rights reserved.
